The Department of Dermatology at the Fourth Affiliated Hospital of Zhejiang University is a National Health Commission-designated training base for standardized residency training in dermatology, a national clinical trial base for drugs and medical devices, one of Zhejiang Province’s first sentinel sites for monitoring adverse reactions to cosmetics, a designated specialized outpatient clinic for psoriasis by the Chinese Medical Association, and the deputy leader of the “Zhejiang Province Psoriasis Diagnosis and Treatment Alliance.” The department currently has a staff of 14, including 1 chief physician, 3 associate chief physicians, 3 attending physicians, 1 senior technician, 5 residents, and 1 technician. All physicians hold master’s degrees or higher and possess national GCP certification. The department is equipped with specialized devices such as the Israeli M22 Super Photon Platform, Q-switched Nd:YAG laser, 1064nm broad-pulse laser, Gold Micro-sculpting CO₂ fractional laser, Miradry microwave system, Peninsula Gold Microneedling Platform, high-frequency electro-ion therapy device, radiofrequency aesthetic device, Sensitive Skin Star treatment system, 308nm excimer laser, UVB phototherapy device, red-blue light therapy devices, and photodynamic therapy devices, as well as professional diagnostic equipment such as dermatoscopy systems and VISIA systems, to meet the diagnostic and treatment needs of patients at various levels. The department has two dedicated standard operating rooms and routinely performs a wide range of surgical procedures, including skin tumor removal, skin flap transfer, hair transplantation, epidermal grafting, non-invasive axillary odor treatment, and minimally invasive excision of various skin lesions, as well as cosmetic injection procedures. Department staff have led or served as principal investigators on numerous research projects funded by the National Natural Science Foundation of China, the Zhejiang Provincial Natural Science Foundation, and the Zhejiang Provincial Public Welfare Technology Research Program. They have conducted over 60 randomized controlled trials, including international and national multicenter studies and trials involving Class 1 innovative drugs. In 2022, the department ranked 35th nationwide in the number of newly initiated projects among dermatology departments. Additionally, staff have published numerous high-quality academic papers as first or corresponding authors in top-tier international journals such as BMJ and iScience.